Drugs / Fluspirilene
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluspirilene | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02374567 ↗ |
| Known as | Fluspirileno | ChEMBL registry synonym — accepted as the source's own label CHEMBL46516 ↗ |
| Known as | Imap | ChEMBL registry synonym — accepted as the source's own label CHEMBL46516 ↗ |
| Known as | MCN-JR-6218 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46516 ↗ |
| Known as | R 6218 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46516 ↗ |
| Known as | Redeptin | ChEMBL registry synonym — accepted as the source's own label CHEMBL46516 ↗ |
| Action | Inhibit | “Dopamine D2 receptor inhibitor” CHEMBL46516 ↗ |
| Modality | Small molecule | — CHEMBL46516 ↗ |
| Target | DRD2 | “Dopamine D2 receptor inhibitor” CHEMBL46516 ↗ |